patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_632591 | REC_0015801 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 3.9 | 60 | male | 1 | 34 | 5.9 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.9 | false | MSS | 2026-03-15T05:36:01.443698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_502655 | REC_0015802 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 15.8 | 79 | female | 1 | 15 | 7.4 | 8 | alectinib 600 mg BID | 12.2 | true | MSI-H | 2026-03-15T05:36:01.444186+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_163985 | REC_0015803 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 19 | 12.6 | 54 | female | 0 | 16 | 4.1 | 0 | alectinib 600 mg BID | 50.3 | false | MSS | 2026-03-15T05:36:01.444618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951723 | REC_0015804 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 14.3 | 73 | male | 1 | 25 | 2.7 | 6 | entrectinib 600 mg daily | 10.5 | true | MSI-H | 2026-03-15T05:36:01.445050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887242 | REC_0015805 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 11.9 | 68 | male | 1 | 22 | 4.7 | 7 | alectinib 600 mg BID | 10.5 | true | MSS | 2026-03-15T05:36:01.445451+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_169044 | REC_0015806 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 14.6 | 65 | female | 0 | 16 | 4.6 | 2 | entrectinib 600 mg daily | 11.2 | false | MSI-H | 2026-03-15T05:36:01.445876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_528831 | REC_0015807 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 5 | 68 | female | 0 | 65 | 5.7 | 8 | carboplatin + paclitaxel + pembrolizumab | 7.2 | false | MSS | 2026-03-15T05:36:01.446285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_448557 | REC_0015808 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 27 | 6.6 | 74 | female | 2 | 27 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 20.6 | true | MSS | 2026-03-15T05:36:01.446679+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_389154 | REC_0015809 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 11.7 | 65 | male | 0 | 1 | 4.4 | 1 | sotorasib 960 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:36:01.447296+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_688601 | REC_0015810 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 19 | 10.4 | 81 | female | 2 | 17 | 6.7 | 4 | sotorasib 960 mg daily | 17.2 | true | MSI-H | 2026-03-15T05:36:01.447714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_719130 | REC_0015811 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 22 | 3.8 | 78 | female | 2 | 66 | 5.1 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.3 | true | MSS | 2026-03-15T05:36:01.448243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_765527 | REC_0015812 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 12.2 | 61 | male | 1 | 17 | 5.6 | 2 | osimertinib 80 mg daily | 15.9 | false | MSS | 2026-03-15T05:36:01.448680+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_433947 | REC_0015813 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 28 | 11 | 64 | male | 1 | 10 | 6.1 | 6 | pembrolizumab 200 mg q3w | 6.3 | true | MSI-H | 2026-03-15T05:36:01.449129+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806392 | REC_0015814 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 29 | 11.7 | 72 | female | 1 | 8 | 5.6 | 1 | osimertinib 80 mg daily | 11.4 | true | MSI-H | 2026-03-15T05:36:01.449528+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_115166 | REC_0015815 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 2.9 | 68 | male | 0 | 9 | 6.2 | 6 | pembrolizumab 200 mg q3w | 17.9 | false | MSS | 2026-03-15T05:36:01.449906+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_161864 | REC_0015816 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 3.7 | 74 | male | 2 | 77 | 8.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.2 | true | MSS | 2026-03-15T05:36:01.450254+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222057 | REC_0015817 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 18 | 13.2 | 62 | female | 0 | 14 | 5.8 | 2 | entrectinib 600 mg daily | 13.1 | true | MSS | 2026-03-15T05:36:01.450639+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_162602 | REC_0015818 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 6.6 | 71 | female | 1 | 50 | 3.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.3 | true | MSS | 2026-03-15T05:36:01.450994+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123359 | REC_0015819 | Non-small cell lung cancer | Adenocarcinoma | III | ALK fusion | 19 | 13.5 | 63 | male | 0 | 14 | 7.1 | 0 | alectinib 600 mg BID | 44.4 | false | MSS | 2026-03-15T05:36:01.451615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_889382 | REC_0015820 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.3 | 84 | female | 1 | 16 | 7.4 | 4 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:36:01.452119+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_565865 | REC_0015821 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 24 | 10.6 | 75 | female | 2 | 16 | 4.1 | 5 | osimertinib 80 mg daily | 11.9 | false | MSI-H | 2026-03-15T05:36:01.452563+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_132200 | REC_0015822 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 4.9 | 66 | female | 1 | 68 | 6.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 4.3 | false | MSS | 2026-03-15T05:36:01.453160+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_934871 | REC_0015823 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 9.7 | 65 | male | 1 | 20 | 5.1 | 2 | osimertinib 80 mg daily | 21.8 | false | MSS | 2026-03-15T05:36:01.453624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_702156 | REC_0015824 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.2 | 63 | female | 1 | 43 | 6.8 | 4 | pembrolizumab 200 mg q3w | 10.5 | false | MSS | 2026-03-15T05:36:01.454027+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_987697 | REC_0015825 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 19.6 | 81 | female | 1 | 20 | 5.2 | 2 | entrectinib 600 mg daily | 8.7 | false | MSS | 2026-03-15T05:36:01.454418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_296060 | REC_0015826 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 14.8 | 51 | female | 0 | 5 | 4.8 | 5 | sotorasib 960 mg daily | 12.9 | true | MSI-H | 2026-03-15T05:36:01.454788+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222249 | REC_0015827 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 12.2 | 58 | female | 1 | 12 | 6 | 6 | alectinib 600 mg BID | 14.4 | false | MSI-H | 2026-03-15T05:36:01.455179+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755198 | REC_0015828 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 26 | 17.9 | 74 | female | 1 | 23 | 5.4 | 0 | osimertinib 80 mg daily | 34.2 | true | MSS | 2026-03-15T05:36:01.455565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_397152 | REC_0015829 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 18 | 12 | 64 | female | 1 | 10 | 4.5 | 4 | osimertinib 80 mg daily | 13.1 | true | MSI-H | 2026-03-15T05:36:01.455949+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_800417 | REC_0015830 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 30 | 5.8 | 74 | female | 3 | 14 | 4.2 | 7 | pembrolizumab 200 mg q3w | 9.6 | true | MSS | 2026-03-15T05:36:01.456391+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578314 | REC_0015831 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 11.6 | 67 | female | 1 | 14 | 5.9 | 1 | entrectinib 600 mg daily | 16.9 | true | MSS | 2026-03-15T05:36:01.456815+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_903747 | REC_0015832 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 15.3 | 73 | female | 0 | 11 | 5.4 | 1 | sotorasib 960 mg daily | 23.4 | false | MSS | 2026-03-15T05:36:01.457221+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845616 | REC_0015833 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 15 | 65 | male | 0 | 16 | 5.6 | 4 | sotorasib 960 mg daily | 12.2 | false | MSI-H | 2026-03-15T05:36:01.457612+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125261 | REC_0015834 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 20 | 72 | male | 1 | 12 | 6.8 | 1 | entrectinib 600 mg daily | 21.2 | true | MSS | 2026-03-15T05:36:01.458001+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_722695 | REC_0015835 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 10.5 | 64 | male | 1 | 16 | 3.9 | 4 | alectinib 600 mg BID | 12 | true | MSI-H | 2026-03-15T05:36:01.458608+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951844 | REC_0015836 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 31 | 8.7 | 65 | male | 0 | 17 | 4.1 | 3 | osimertinib 80 mg daily | 12.5 | false | MSS | 2026-03-15T05:36:01.459061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_575944 | REC_0015837 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 10.9 | 66 | female | 1 | 18 | 4.7 | 8 | osimertinib 80 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:36:01.459475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_517373 | REC_0015838 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 31 | 8 | 71 | female | 2 | 17 | 6 | 8 | pembrolizumab 200 mg q3w | 13.5 | false | MSS | 2026-03-15T05:36:01.459929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_426834 | REC_0015839 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 12.3 | 63 | female | 0 | 13 | 4.9 | 3 | osimertinib 80 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:01.461150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275736 | REC_0015840 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 14.5 | 71 | female | 1 | 16 | 5.5 | 4 | osimertinib 80 mg daily | 9.1 | true | MSS | 2026-03-15T05:36:01.461628+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_340233 | REC_0015841 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 10.3 | 60 | male | 1 | 18 | 5.2 | 6 | pembrolizumab 200 mg q3w | 11.6 | true | MSS | 2026-03-15T05:36:01.462029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_271067 | REC_0015842 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 11.9 | 65 | male | 1 | 12 | 4.9 | 5 | osimertinib 80 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:36:01.462459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967357 | REC_0015843 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 25 | 4 | 65 | female | 1 | 20 | 5 | 1 | osimertinib 80 mg daily | 19.4 | false | MSS | 2026-03-15T05:36:01.462851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_804659 | REC_0015844 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 24 | 12.5 | 74 | female | 2 | 20 | 5.6 | 5 | alectinib 600 mg BID | 15.4 | true | MSS | 2026-03-15T05:36:01.463433+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223718 | REC_0015845 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 30 | 12.1 | 74 | female | 1 | 11 | 5.9 | 2 | alectinib 600 mg BID | 15.9 | true | MSS | 2026-03-15T05:36:01.463919+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_896112 | REC_0015846 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 28 | 11.4 | 69 | female | 0 | 3 | 4.9 | 7 | entrectinib 600 mg daily | 7.7 | false | MSS | 2026-03-15T05:36:01.464641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_631949 | REC_0015847 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 24 | 7.2 | 56 | male | 1 | 20 | 5.3 | 1 | entrectinib 600 mg daily | 14.2 | true | MSS | 2026-03-15T05:36:01.465305+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108020 | REC_0015848 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 26 | 13.3 | 66 | female | 1 | 16 | 6.1 | 7 | entrectinib 600 mg daily | 12 | true | MSS | 2026-03-15T05:36:01.466076+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647957 | REC_0015849 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 18 | 9.8 | 80 | female | 1 | 28 | 5.9 | 3 | osimertinib 80 mg daily | 9.5 | false | MSS | 2026-03-15T05:36:01.466557+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_278340 | REC_0015850 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 16 | 11.6 | 76 | female | 2 | 15 | 5.6 | 2 | sotorasib 960 mg daily | 17.9 | false | MSI-H | 2026-03-15T05:36:01.466999+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_430152 | REC_0015851 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 17 | 5.9 | 61 | male | 1 | 14 | 5.5 | 6 | pembrolizumab 200 mg q3w | 6.3 | false | MSS | 2026-03-15T05:36:01.467446+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488052 | REC_0015852 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 11.4 | 64 | male | 1 | 10 | 8.6 | 7 | sotorasib 960 mg daily | 10.9 | false | MSI-H | 2026-03-15T05:36:01.467883+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_986626 | REC_0015853 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 31 | 10.8 | 75 | female | 1 | 13 | 4.1 | 1 | sotorasib 960 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:36:01.468485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116938 | REC_0015854 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 9.1 | 77 | female | 2 | 13 | 6.7 | 5 | osimertinib 80 mg daily | 4.3 | true | MSS | 2026-03-15T05:36:01.468955+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_539205 | REC_0015855 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 13.7 | 55 | female | 1 | 13 | 7.5 | 4 | sotorasib 960 mg daily | 8 | false | MSS | 2026-03-15T05:36:01.469389+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_603108 | REC_0015856 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 13.9 | 61 | female | 0 | 21 | 4.2 | 2 | pembrolizumab 200 mg q3w | 14.5 | false | MSI-H | 2026-03-15T05:36:01.469845+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_761198 | REC_0015857 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 29 | 11.8 | 74 | female | 2 | 5 | 5.9 | 1 | pembrolizumab 200 mg q3w | 20.6 | true | MSS | 2026-03-15T05:36:01.470246+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_438236 | REC_0015858 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 14 | 73 | female | 1 | 15 | 5.4 | 8 | osimertinib 80 mg daily | 5.8 | true | MSS | 2026-03-15T05:36:01.470590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326044 | REC_0015859 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 19 | 12.9 | 59 | female | 0 | 5 | 5.7 | 1 | sotorasib 960 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:01.471060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648399 | REC_0015860 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 13.9 | 61 | male | 0 | 4 | 4.5 | 7 | sotorasib 960 mg daily | 15.6 | false | MSS | 2026-03-15T05:36:01.471727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_686642 | REC_0015861 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 28 | 11.3 | 66 | female | 1 | 17 | 5.5 | 4 | osimertinib 80 mg daily | 15.5 | false | MSI-H | 2026-03-15T05:36:01.472919+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123049 | REC_0015862 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 10 | 61 | male | 0 | 5 | 5.5 | 8 | osimertinib 80 mg daily | 13.9 | true | MSS | 2026-03-15T05:36:01.473457+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723141 | REC_0015863 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 20 | 12 | 80 | female | 1 | 12 | 7.6 | 1 | osimertinib 80 mg daily | 10.2 | true | MSS | 2026-03-15T05:36:01.473959+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_518324 | REC_0015864 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 20 | 8.2 | 51 | male | 0 | 17 | 5.1 | 6 | entrectinib 600 mg daily | 16 | false | MSS | 2026-03-15T05:36:01.474397+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_142911 | REC_0015865 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 19 | 13.7 | 63 | female | 0 | 21 | 7.2 | 1 | osimertinib 80 mg daily | 27.5 | false | MSI-H | 2026-03-15T05:36:01.474832+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_402439 | REC_0015866 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 29 | 17.3 | 71 | female | 2 | 17 | 5.5 | 2 | alectinib 600 mg BID | 24.6 | false | MSI-H | 2026-03-15T05:36:01.475243+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_359695 | REC_0015867 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 10.9 | 80 | male | 2 | 8 | 2.6 | 5 | osimertinib 80 mg daily | 14.6 | false | MSI-H | 2026-03-15T05:36:01.475658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573681 | REC_0015868 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 2.7 | 62 | female | 1 | 21 | 6 | 6 | osimertinib 80 mg daily | 14.2 | true | MSS | 2026-03-15T05:36:01.476047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_964005 | REC_0015869 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 10.6 | 81 | female | 1 | 0 | 5.4 | 6 | alectinib 600 mg BID | 12.2 | true | MSI-H | 2026-03-15T05:36:01.476492+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_326563 | REC_0015870 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 17.2 | 72 | male | 3 | 13 | 6 | 5 | alectinib 600 mg BID | 15.6 | true | MSI-H | 2026-03-15T05:36:01.476917+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764875 | REC_0015871 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 27 | 14.2 | 53 | male | 0 | 7 | 7.2 | 2 | osimertinib 80 mg daily | 15.4 | false | MSI-H | 2026-03-15T05:36:01.477331+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_443336 | REC_0015872 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 27 | 19.9 | 54 | female | 0 | 16 | 7.6 | 0 | osimertinib 80 mg daily | 17 | false | MSI-H | 2026-03-15T05:36:01.477746+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_910576 | REC_0015873 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 7.3 | 71 | female | 1 | 67 | 4.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 15.3 | false | MSS | 2026-03-15T05:36:01.478136+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_330806 | REC_0015874 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 19.8 | 75 | female | 1 | 17 | 3.7 | 6 | entrectinib 600 mg daily | 12.2 | false | MSS | 2026-03-15T05:36:01.478756+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_970934 | REC_0015875 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 22 | 15.6 | 69 | male | 0 | 21 | 3.9 | 7 | sotorasib 960 mg daily | 6.6 | true | MSS | 2026-03-15T05:36:01.479184+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967734 | REC_0015876 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 14 | 13.4 | 57 | female | 0 | 17 | 3.8 | 1 | entrectinib 600 mg daily | 15.7 | true | MSI-H | 2026-03-15T05:36:01.479764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_626182 | REC_0015877 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 9.2 | 69 | female | 0 | 5 | 4.4 | 4 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:36:01.480320+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_210452 | REC_0015878 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 15 | 4.7 | 62 | male | 0 | 16 | 5.7 | 2 | pembrolizumab 200 mg q3w | 15.4 | false | MSS | 2026-03-15T05:36:01.480740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_494440 | REC_0015879 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 22 | 5.4 | 69 | female | 0 | 56 | 3.6 | 6 | pembrolizumab 200 mg q3w | 11.3 | true | MSS | 2026-03-15T05:36:01.481157+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220139 | REC_0015880 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 23 | 7.1 | 61 | male | 1 | 19 | 8.1 | 6 | pembrolizumab 200 mg q3w | 4.7 | false | MSS | 2026-03-15T05:36:01.481593+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_313469 | REC_0015881 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 28 | 6.4 | 59 | female | 1 | 67 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:36:01.482007+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_251558 | REC_0015882 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 24 | 7.4 | 70 | female | 3 | 19 | 7.5 | 2 | pembrolizumab 200 mg q3w | 22 | true | MSS | 2026-03-15T05:36:01.482415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_179950 | REC_0015883 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 2.8 | 53 | male | 0 | 53 | 6.4 | 1 | carboplatin + paclitaxel + pembrolizumab | 4.5 | true | MSS | 2026-03-15T05:36:01.482810+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_589808 | REC_0015884 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 17.4 | 72 | female | 2 | 14 | 5.9 | 5 | sotorasib 960 mg daily | 11.5 | false | MSI-H | 2026-03-15T05:36:01.483168+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_116951 | REC_0015885 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 16.5 | 56 | female | 1 | 16 | 6.7 | 6 | entrectinib 600 mg daily | 14.6 | false | MSS | 2026-03-15T05:36:01.483565+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_488092 | REC_0015886 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11.9 | 75 | female | 1 | 19 | 5.9 | 7 | osimertinib 80 mg daily | 14.7 | true | MSI-H | 2026-03-15T05:36:01.483976+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783060 | REC_0015887 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 4.6 | 73 | female | 2 | 60 | 7.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 13.4 | true | MSS | 2026-03-15T05:36:01.484609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331859 | REC_0015888 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 33 | 6.4 | 66 | female | 1 | 36 | 6 | 1 | carboplatin + paclitaxel + pembrolizumab | 22 | true | MSS | 2026-03-15T05:36:01.485059+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_968942 | REC_0015889 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 11.6 | 69 | female | 0 | 9 | 7.5 | 1 | osimertinib 80 mg daily | 23.8 | true | MSS | 2026-03-15T05:36:01.485445+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_493675 | REC_0015890 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5 | 61 | male | 1 | 20 | 5.8 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.7 | true | MSS | 2026-03-15T05:36:01.485836+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_977266 | REC_0015891 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 16.1 | 65 | female | 1 | 22 | 5.2 | 4 | entrectinib 600 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:36:01.486265+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_230057 | REC_0015892 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 8.1 | 56 | female | 0 | 17 | 5.3 | 5 | osimertinib 80 mg daily | 4.1 | true | MSS | 2026-03-15T05:36:01.486658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_436990 | REC_0015893 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 8.4 | 66 | female | 1 | 20 | 5.4 | 2 | sotorasib 960 mg daily | 9.5 | true | MSS | 2026-03-15T05:36:01.487047+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_144988 | REC_0015894 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 24 | 15 | 65 | female | 0 | 10 | 5.4 | 5 | entrectinib 600 mg daily | 8.3 | false | MSS | 2026-03-15T05:36:01.487418+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_648630 | REC_0015895 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 9.4 | 66 | female | 2 | 12 | 5.2 | 8 | sotorasib 960 mg daily | 13.4 | false | MSS | 2026-03-15T05:36:01.487783+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_657440 | REC_0015896 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 24 | 5 | 75 | female | 1 | 58 | 6.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 25.6 | true | MSS | 2026-03-15T05:36:01.488214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_711938 | REC_0015897 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 21 | 5.8 | 70 | female | 1 | 12 | 5.8 | 1 | pembrolizumab 200 mg q3w | 13.3 | true | MSS | 2026-03-15T05:36:01.488615+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_559537 | REC_0015898 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 7.7 | 66 | female | 1 | 20 | 4.6 | 2 | entrectinib 600 mg daily | 20.9 | true | MSS | 2026-03-15T05:36:01.489000+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883252 | REC_0015899 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 11.9 | 67 | female | 0 | 13 | 6.1 | 7 | osimertinib 80 mg daily | 14.7 | false | MSI-H | 2026-03-15T05:36:01.489383+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_961653 | REC_0015900 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 13.2 | 72 | female | 2 | 13 | 6.9 | 1 | osimertinib 80 mg daily | 21.6 | true | MSS | 2026-03-15T05:36:01.489948+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.